CTKB
Cytek Biosciences
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
Signals Analysis
Buy signal 3
Sell signal 0
consensus rating "Buy"
Revenue Beats Expectation
EPS Beats Expectation
Key Stats
--DAY`S RANGE--
--52 WK RANGE--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
About CTKB
Cytek Biosciences, Inc.
A leading cell analysis solutions company
Life Science Tools and Services
Invalid Date
07/23/2021
NASDAQ Stock Exchange
648
12-31
Common stock
47215 Lakeview Blvd. Fremont, California 94538
--
Cytek Biosciences, Inc., was incorporated in Delaware in December 2014. The company is a leading cell analysis solutions company, advancing the next generation of cell analysis tools with a novel technical approach to differentiate fluorescent tags on a single cell using full-spectrum fluorescence features from multiple lasers (" Full Spectrum Analysis "or" FSP "technology). The company's goal is to become a premier cell analysis company through continuous innovation, contributing to scientific progress in biomedical research and clinical applications.
Company Financials
EPS
CTKB has released its 2024 Q4 earnings. EPS was reported at 0.12, versus the expected 0.10, beating expectations. The chart below visualizes how CTKB has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
CTKB has released its 2024 Q4 earnings report, with revenue of 57.48M, reflecting a YoY change of -1.30%, and net profit of 9.64M, showing a YoY change of 75.23%. The Sankey diagram below clearly presents CTKB’s revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
